Marisa McGinley (Mellen Center, Cleveland Clinic Main Campus, Ohio, USA) shared her expert insights with us on the most significant developments in the treatment of multiple sclerosis (MS) over the past year.
1. What are the current unmet needs in multiple sclerosis (MS) treatment? (0:04)
2. What have been the most important recent advances in the treatment of primary progressive MS? (0:42)
3. Which patients with secondary progressive MS are most likely to benefit from siponimod? (1:11)
4. When should we begin treatment for progressive MS? (2:36)
5. How can quantitative MRI data be used in routine MS clinical practice? (3:51)
6. How important are patient reported outcomes in clinical decision-making? (5:18)
Speaker disclosures: Marisa McGinley serves as a consultant for Genzyme and Genentech.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2021: Flushing and Flushing-related Adverse Events – Results from the Phase 3 EVOLVE-MS-2 Study
It was a pleasure to meet with Dr Barry Singer (The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA) to discuss the results of the phase 3 EVOLVE-MS-2 study, specifically looking at flushing and flushing related-adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis. The abstract […]
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!